< PreviousMERGERS & ACCUSITIONS30Pharma Business International www.pbiforum.net&D<5D?DE;C=E1DD?ECE-D2E6<C2D>EA?B;DE+*E=6C:DE@/D>EB;DE<C=BE3D4E2DC>=C?9E8C9DE76E=D/D>C<E@3EB;DE9DC<=E4DD"6<@>D9EA?E<C=BEA==7D,=E>@7?9(760E@44D,>DE=DDA?5E8C?2E@3EB;DE9DC<=EABE=B>7:-97>A?5EB;DE=BC>BE@3EB;DE2DC>E:@8DEA?B@3>7ABA@?0E&;AD3EC8@?5EB;D8EA=EAB=EE1A<<A@?C:$7A=ABA@?E@3E7?@E);D>C6D7BA:=E4;A:;:@86<DBD9EA?EDC><2E+C>:;0E);DE9DC<E=DD=&D<5D?DEC99E?@/D<EBD:;?@<@52EC?9C9/C?:D9E8C?73C:B7>A?5E:C6C1A<ABAD=EB@AB=E:@88D>:AC<E6@>B3@<A@EC?9E6A6D<A?DE@3@?:@<@52EB;D>C6AD=0E*BEB;A=E>CBD.EB;D:@86C?2E>DC<<2E4A<<E>DC:;EAB=ECA8E@31D:@8A?5ECE<DC9D>EA?E5<@1C<E:D<<7<C>A887?@B;D>C620+@/A?5E@?.E4DEB7>?E@7>ECBBD?BA@?EB@<C"@#8AB;<A?D0E);A=E6C>BA:7<C>E9DC<E=C4B;DE6;C>8CE1A54A5E>DC:;EC?EC5>DD8D?BB@E172E@/C>BA=,E 0E6D>E:D?BE=BC-DEA?EA?B;DE:@86C?2,=E&@?=78D>EDC<B;E@A?BD?B7>DE3@>E0!E1A<<A@?0E@@-A?5ECBEB;DE3A?C?:AC<E6C>BA:7<C>=E@3B;DE@A?BE/D?B7>DEC?9EAB,=EDC=2EB@E=DDE4;2#E4@7<9E4C?BE8@>DE:@?B>@<0EC=BE2DC>.B;DE17=A?D==E>D6@>BD9E=C<D=EA?ED":D==E@30 E1A<<A@?EC?9.E=A?:DE!%'.E=C<D=E;C/D5>@4?E E6D>E:D?BE@?ECEB;>DD(2DC>E&*1C=A=E4AB;EC?E@/D>C<<EA86>@/D8D?BEA?@6D>CBA?5E8C>5A?=E3>@8E''0 E6D>E:D?BEB@'0E6D>E:D?BEA?E!%'0E*?9EB;D?EB;D>D,=E#C?@3AE4;@.EB@E9CBD.C>DE<DC9A?5EB;D:;C>5DE4;D?EABE:@8D=EB@E87<BA(1A<<A@?E9@<<C>E9DC<=0E+C>:;E=C4EB;D:@86<DBA@?E@3EAB=E''0E1A<<A@?EC:$7A=ABA@?@3E;CD8@6;A<AC(3@:7=D91A@6;C>8C:D7BA:C<EA@/D>CBA/0E*=E4AB;=@8DE@3EB;DEC1@/DE9DC<=.EB;A=EC:$7A=ABA@?4C=E@>A5A?C<<2EC??@7?:D9EA?EC?7C>2.5A/A?5E;@6DEB@E8C?2EB;CBE!%' E4@7<9E1DCE8A<D=B@?DE2DC>E3@>EB;DE+*E8C>-DB0E#@<@?5EC=EB;DE8C@>E6<C2D>=E=7:;EC=E#.&D<5D?DEC?9E#C?@3AE-DD6EC:$7A>A?5E4AB;B;A=E=C8DEBD?C:AB2.EB;D?EABE8C2E7=BE1DECBB;CB0E?9DD9.EB;D>DEC>DEC<>DC92E=A5?=EB;CB!%' E:@7<9E/D>2E4D<<E1DECE>D:@>9(1>DC-A?5E2DC>E3@>EB;DE6;C>8CE+*8C>-DB0E*=E4D<<EC=EB;DE1A5E9DC<=E4D,/DC<>DC92ED"6<@>D9.EB;D>DEC>DE=@8DE=8C<<D>9DC<=E1D<@4EB;DE1A<<A@?E9@<<C>E8C>-EB;CBC>DE4@>B;E8D?BA@?A?50E#DCBB<DED?DBA:=.3@>ED"C86<D.E;C=E>D:D?B<2E:@86<DBD9EAB=' E8A<<A@?EC:$7A=ABA@?E@3E&C=:C9AC?);D>C6D7BA:=EA?ECE9DC<EB;CBE5>C?B=EAB5<@1C<E>A5;B=EB@EA?/D=BA5CBA@?C<E@>C<B2>@=A?DE-A?C=DEA?;A1AB@>.E)7:CBA?A10*E3D4E8A<<A@?E9@<<C>=E>A:;D>EC?9E4DE3A?9&;C><D=EA/D>EC1@>CB@>AD=E=6D?9A?5 %%E8A<<A@?E@?EB;DEC:$7A=ABA@?E@3E+D=DC>:;0E);DE9DC<E=B>D?5B;D?=EB;D3@>8D>,=EC1A<AB2EB@6C>B?D>E4AB;E:<AD?B=C:>@==EB;DE9>75E9A=:@/D>2EC?99D/D<@68D?BE:@?BA?7780E&;CA>8C?EC?9&EC8D=E&0E@=BD>E=CA9EB;DC:$7A=ABA@?EC<=@EC99D9EC::D==EB@5>@4A?5ED?9E8C>-DB=.E;A5;($7C<AB2=D>/A:D=.E=:AD?BA3A:ED"6D>BA=D.EC?9:@86<D8D?BC>2E:C6C1A<ABAD=0C=B<2E4DEB7>?E@7>ECBBD?BA@?EB@EB;D%E8A<<A@?E9DC<E4;A:;E=C4E7?91D:-C:$7A>DE>D"B@?);D>C6D7BA:=0E);D=6D:A3A:=E@3EB;DE9DC<=C4E7?91D:-E8C-DC?E763>@?BE6C28D?BE@3'%%E8A<<A@?E6<7=E76EB@ %E8A<<A@?EA?9D/D<@68D?B.E>D57<CB@>2EC?9=C<D=E8A<D=B@?D=0);CB,=ECE4>C6E@?EB;A=EA==7D,=E+*>@7?9(76.E17BE1DE=7>DEC?9E:;D:-E1C:-EA?7?DE4;D>DE4D,<<E:@?BA?7DEB@E:;>@?A:<DB;DE1D=BE@3E6;C>8C,=E9DC<(8C-A?5.E1@B;1A5EC?9E=8C<<0© Shutterstock / Atstock Productions28-31_Layout 1 11/04/2018 10:52 Page 3Pharma Business International 31www.pbiforum.netMERGERS & ACCUSITIONS© Shutterstock / BurAnd28-31_Layout 1 11/04/2018 10:52 Page 4COLD CHAIN32Pharma Business International www.pbiforum.net31)253*904/-90,75395368*256'951973953-)162'#8'16438973-90256507/96496,89-8./4'+83694(9,5*,.82(42+53*968+.8276)289043624//8-9.70#7*53*14/)65431"94284&82%9569!866829831)28196,8917(8973-180)28962731.4267654394(95+.426736.,72+708)6507/9.24-)061%9719-7+986%528064294(9 42/-$5-8972#8653*9(42 8/5954,82+7/98./7531"9,89+72#869(4262731.42653*968+.8276)281831565&89+768257/19(426,89,87/6,07289+72#86%1)0,971.,72+708)6507/1%!/44-%96511)8973-42*7319519791)!18*+836%90)22836/'&7/)8-9767..245+768/'9!5//543973-98.8068-964*24$96497..245+768/'9!5//5439!'9%9,817'1"9 56,96,89.,72+708)6507/04+.735819-8&8/4.53*98&829+42804+./8973-968+.8276)2891831565&8-2)*1%96,828951979*2876829-8+73-9649.24&5-85+.24&8-9.70#7*53*9.82(42+7308973-98((505830'$56,539044/90,7539/4*516501"9695197/149&567/9649831)286,828951979180)28%904+./57369044/90,7539(24+-8./4'+83694(91,5.+83619649/7169+5/89-8/5&82'"93979!5-9649831)289 944-951625!)6543 2706508928*)/765431972897-,828-9649$56,539044/0,7539/4*516501%95334&76543973-938$9680,34/4*5819728.24&53*9.727+4)3696496,898+82*8308973-98&4/)65434(91+726968+.8276)289043624//8-9.70#7*53*.24680653*9.,72+708)6507/9.7'/47-19$42/-$5-8"930287153*/'9.70#7*53*904+.73581972853042.427653*95334&765&89-815*39(876)281973-)65/5153*9+42897-&7308-9680,34/4*581%$,50,9,8/.98/5+53768968+.8276)2880)215431973-9+886928*)/7642'28)528+8361"9395+.86)19(426,89/768169*83827654394(.70#7*53*9.24-)06104+8197196,89.,72+753-)162'9043653)81964*24$97697915*35(507362768" 4185-43%94(9$,50, 8/5951979.726%9519738$/'9/7)30,8-9187(285*,69.24*27++8(40)118-94395+.24&53*04//7!427653*973-5368*2765439!86$883.,72+79+73)(706)2821973-6,8529/4*516501914/)6543.24&5-821"9 4185-439519791879(285*,69+4-8/70#34$/8-*53*973-91)..42653*96,895365+76853682043380654394(96,898365289.,72+7/4*51650191)../'0,753953942-829649!866829831)2896,8917(8973-9180)2862731.4267654394(9.,72+708)6507/9.24-)061%929868./7531"99 )6915+./'%9 4185-439.24&5-81979187(285*,69 Keeping coldIt’s in the industry’s best interest to maintain cold chain integrity throughout the entire supply chain,both to preserve product integrity and also to safeguard the patients’ dependent upon it. 34 Á© Shutterstock / kokliang32-34_Layout 1 11/04/2018 10:55 Page 1© Shutterstock / ESB Professional 32-34_Layout 1 11/04/2018 10:55 Page 2COLD CHAIN34Pharma Business International www.pbiforum.net04+./57369+4-8/%9831)253*96,8917(8973-180)28962731.4267654394(9.,72+708)6507/.24-)06196,24)*,4)696,898365289.,72+7/4*51650191)../'90,753"9,89.24*27+(40)181943973940873*453*97..2470,96468+.8276)289043624//8-9.,72+708)6507/62731.42676543%9$,50,94((8219/4$62731.42676543904161%9+535+7/83&5243+8367/95+.706973-9+535+518-68+.8276)28980)2154319-)253*9/43*,7)//4*516501"9 )22836/'9724)3-994(.,72+708)6507/9.7'/47-197289+4&8-9&57408739(285*,69,4$8&8295619(428071696,51$5//95302871896497..245+768/'99$56,536,8938699'8721%92986917'1"93-68+.8276)289043624//8-91,5.+83619$5//9!879.72694(96,76%9,4$8&8295619+4289/5#8/'964!89+7-89).94(9.7'/47-196,76972891,8/(167!/89429,7&8979$5-82968+.8276)28273*8"9,89 4185-439.24*27+9519*24)3-!287#53*99-)896495619 904+./5736376)28996,8289519346,53*98706/'9/5#8956"99 70#7*53*904+.73581972897/14530287153*/'9)65/5153*97-&7308-971186+737*8+836914(6$72891'168+19649831)28.,72+708)6507/1972891,5..8-96496,8925*,6/4076543%97696,8925*,6965+8973-90256507//'%6,7696,8'97225&895396,8925*,69043-56543",8953-)162'95197/14918853*979*24$53*6283-9649-8./4'928)17!/891'168+104)./8-9$56,9711869+737*8+83697714(6$728971979182&508973-9287.53*96,8711405768-9!838(561"9,81891'168+190737)64+76507//'904//806973-9737/'189-767(24+904+.73'9-7679/4**8294)6.)61"99 )22836/'94.827653*95396,89+72#8695197273*894(9779.24-)0619.24&5-53*04//806543973-9737/'15194(9!273-7*3416501831429-767%97195619/53#8-964979&72586'94(1+7269.70#7*53*94.6543197//4$53*.70#7*53*9&83-42196496270#979-5&82156'94(-7679530/)-53*9&5!276543%9/5*,6%9,)+5-56'%68+.8276)28973-9+428",89-7679286258&8-973-91,728-9073,8/.9.,72+708)6507/904+.735819+7#8+428953(42+8-90,4508194396,89+4167..24.257689.70#7*53*91'168+1964-8./4'%9-8.83-53*94396,891.805(501,5..53*9/7381973-924)68196,8529.7'/47-$5//937&5*768"9346,8296283-95196,89+4&8964$72- 96270#53*%9$,50,9$4)/-9388-9649!8+737*8-9&579/)86446,%9942+73)7//'107338-9!7204-819$,828!'.,72+708)6507/904+.73581907396270#.70#7*81%973-96,85291,5.+8369.24*2811%43/538"969519.28-5068-97-&7308+8361953 96270#53*94.654319&579797791'168+$5//9!89.72694(96,8953-)162'95396,893872()6)28"5&8396,891,88295+.426730894(96,8904/-0,753%95691,4)/-904+897193491)2.2518964-5104&8296,89/8&8/94(95334&76543973-938$-8&8/4.+8361%91)0,9719 4185-43%967#53*./708"9© Shutterstock / Anamaria Mejia32-34_Layout 1 11/04/2018 10:55 Page 3Vitafoods Europe 2018Pharma Business International 35www.pbiforum.net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or more information and toregister for free, visitwww.vitafoods.eu.com or getinvolved on Twitter@VitafoodsEurope.Taking place between 15-17 May 2018 in Palexpo, Geneva, Vitafoods Europe offers the most complete marketoverview of nutraceutical ingredients in the world. PHOTOS COURTESY OF INFORMA EXHIBITIONS VITAFOODS35_Layout 1 11/04/2018 10:57 Page 1(!/234859*9)9%214859*9$"21,11th European BiosimilarsCongress 0,148596690&79$/27,18918$/27,18+9-8,59B@7D=D:C;=:CDA4DC+5C?BC>;CD@ADB@<D>=8C.@7CD%6?A5C=>DBA<B8B9=?<D#A>3?C<<D7=<-C;A8CD=D@?6<@C:D8CC@B>3D3?A6>:D07C?C-BA<B8B9=?D5=?@>C?<D=8=<<D@AD=::?C<<D@7C5?C<C>@D=>:D46@6?CD;A>:B@BA>DA4D@7CD8=?,C@DB>%6?A5C2D'7B<D/C=?<DC:B@BA>D0B99D4A;6<DA>-BA<B8B9=?DB85?A1C8C>@D=>:D@7CD-6<B>C<<?C6B?C8C>@<D4A?DA?3=>B<=@BA><D@7=@D,CC5DA><CC,B>3D)&DC>:A?<C8C>@2D)A?D8A?CB>4A?8=@BA>.DC8=B9C6?A-BA<B8B9=?<57=?8=;C6@B;=9;A>4C?C>;C<2;A82(/7348599)9#7467348599'85Formulation and DrugDelivery Congress7-76/7391-0218+906406'7CD)A?869=@BA>D=>:D?63DC9B1C?/#A>3?C<<D0B99D;A1C?D=?C=<D9B,CDA5@B8B<B>34A?869=@BA>.DB85?A1B>3D:?63D:C9B1C?/.PharmaEVENTS(/734859.9)9(!/234859.9$"21,INTERPHEX81-3976-27+979 029&99D@7CD<A96@BA><D/A6D>CC:D@AD;A<@(C44C;@B1C9/:C1C9A5D=>:D8=>64=;@6?CD6=9B@/D5?A:6;@<D=?C=1=B9=-9CD=@D$'%!%DD@7CD57=?8=.D-BAD=>::C1B;CD:C1C9A58C>@DC1C>@2DC?CD/A6D;=>D4B>:D=99DA4@7CD<@=@C(A4(@7C(=?@D<A96@BA><D/A6D;A69:D5A<<B-9/>CC:2D$@DB<D:C:B;=@C:D@ADB>>A1=@BA>.D@C;7>A9A3BC<=>:D,>A09C:3C.D0B@7D=D4A;6<DA>D@7CDC>@B?CD5?A:6;@:C1C9A58C>@D9B4CD;/;9C2D)A?D8A?CDB>4A?8=@BA>.D1B<B@0002B>@C?57C+2;A82© Shutterstock / Syda Productions#746734859*9)9(!/234859*./67Chemspec Europe 201807,6&7337+972&8659#7C8<5C;DB<D%6?A5C<D5?C8BC?D<A6?;B>3=>:D>C@0A?,B>3DC1C>@D4A?D@7CD4B>CD=>:<5C;B=9B@/D;7C8B;=9<DB>:6<@?/2D'7CC+7B-B@BA>DB<D@7CD;C>@?=9D8=?,C@59=;CD4A?8=>64=;@6?C?<.D<6559BC?<D=>:D:B<@?B-6@A?<A4D4B>CD=>:D<5C;B=9B@/D;7C8B;=9<D@AD8CC@0B@7D56?;7=<C?<D=>:D=3C>@<D9AA,B>3D4A?<5C;B=9B<C:D5?A:6;@<DA?D-C<5A,CD<A96@BA><2$@D5?A1B:C<D=>DC+@C><B1CDC:6;=@BA>5?A3?=88CDA4D9C;@6?C<D=>:D;A>4C?C>;C<C<<BA><DA>(<B@C2D$>D4A6?D:C<B3>=@C:D9C;@6?C@7C=@?C<.DB>:6<@?/DC+5C?@<D0B99D7A9:D@=9,<=>:D:B<;6<<BA>D?A6>:<DA>D=D1=?BC@/DA4B>:6<@?/D@A5B;<2D)A?D8A?CDB>4A?8=@BA>.D1B<B@0002;7C8<5C;C6?A5C2;A8"* C>39B<7236Pharma Business International www.pbiforum.net© Shutterstock / f11 photo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harma Tech 2018 58--977659388+98"867=?8=D'C;7D"* DB<D=D59=@4A?8D=B8C:D=@=B:B>3DC44B;BC>;/D:?63D:B<;A1C?/D=>::C1C9A58C>@2D$@DB>;96:C<D5?A85@D,C/>A@C5?C<C>@=@BA><.DA?=9D@=9,<.D5A<@C?D5?C<C>@=@BA><=>:DC+7B-B@BA><DC><6?B>3D:C9C3=@C<D;=>D<@=/D65@AD:=@CD0B@7D@7CD1C?/D9=@C<@DB>:6<@?/:C1C9A58C>@<2D)A?D8A?CDB>4A?8=@BA>.D1B<B@000257=?8=@C;7257=?8=;C6@B;=9;A>4C?C>;C<2;A82#746734859.9)9%214859.9'85World Precision MedicineCongress/31673397316976-27+9064069)?A8D;9B>B;=9D:C1C9A58C>@<D@AD5?B;B>3.?CB8-6?<C8C>@D=>:D8=?,C@D=;;C<<.D@7B<36-37_Layout 1 11/04/2018 11:00 Page 1#746734859.9)9(!/234859.'85Injectable Drug Delivery 0,1485966976316-069%02/&+06406A<@C:D-/DBD?A65.D@7B<D-?=>:D>C0;A>4C?C>;CD4A?D"* D0B99DC+59A?CD@7C-AA8B>3DB>C;@=-9CD:?63D:C9B1C?/D8=?,C@2&;;A?:B>3D@AD!C<C=?;7D=?,C@<D!C5A?@.D@7C8=?,C@DB<DC+5C;@C:D@AD?C=;7D 2D-B99BA>-/D"*"*2D'7C?C4A?C.D@7B<D;A>4C?C>;CD=B8<D@A:B<;6<<D@7CD>C+@D3C>C?=@BA>DA4DB>C;@=-9C:?63<D=>:D:C1B;C<D@7?A637DC+59A?B>3C8C?3B>3D@C;7>A9A3BC<D=>:D>C0D8=?,C@A55A?@6>B@BC<2D)A?D8A?CDB>4A?8=@BA>.D1B<B@0002<8B(A>9B>C2;A26,2(/734859**9)9#746734859*'85PharmacovigilanceEurope 1,-069064069,5&"189'7B<D7B379/D=>@B;B5=@C:D;A>4C?C>;CDA44C?<=>DA55A?@6>B@/D=>:D59=@4A?8D@AD<7=?CC+5C?BC>;C<D0B@7D9B,C8B>:C:DB>:B1B:6=9<DB>www.pbiforum.netPharma Business International 37© Shutterstock / Caron Badkin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aking Pharmaceuticals10!9$2768+9076-25+9B99C:D=<D@7CD9C=:B>3DD57=?8=;C6@B;=9DC1C>@.=,B>3D7=?8=;C6@B;=9<D-A=<@<D4B1CD?AA8<D=>:DA1C?D 7A6?<DA4D4?CC(@A(=;;C<<D57=?8=;C6@B;=9D;A>@C>@2D=<@/C=?D<=0D@7CD>68-C?DA4D=@@C>:CC<D?B<CD-/D=98A<@D*.=>:D@7B<D/C=?DB<D<C@D@AD-CD-C@@C?D@7=>DC1C?2D)A?D8A?CB>4A?8=@BA>.D1B<B@D00028=,B>357=?8=2;A8236-37_Layout 1 11/04/2018 11:00 Page 2FEATURESAids & HIV exposéM&A round-upPPEWaste management DistributionLaboratoriesNext issue:Deadline - 30th May 2018REGULARSNewsEventsPharmaBUSINESS INTERNATIONALVisit us atwww.pbiforum.netwhere you’ll find thelatest news as it breaks – and why not subscribe to ournewsletters so you can have thelatest news emailed to yourinbox, in betweenprinted issues?@pbiforumwww.pbiforum.netcompany/pbiforum38_Layout 1 11/04/2018 11:01 Page 1Next >